<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Biotech companies</title>
	<atom:link href="http://www.psa-rising.com/blog/category/pca/biotech-companies/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Wed, 25 Nov 2009 18:36:49 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.6</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Provenge Trial Ongoing &amp; Recruiting At Eight US Centers</title>
		<link>http://www.psa-rising.com/blog/2009/11/provenge-open-label-trial/</link>
		<comments>http://www.psa-rising.com/blog/2009/11/provenge-open-label-trial/#comments</comments>
		<pubDate>Wed, 25 Nov 2009 18:18:45 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[Sipuleucel-T]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2269</guid>
		<description><![CDATA[An open-label study of Sipuleucel-T (Provenge) is ongoing at 8 centers across the USA. This is a Phase 2 Study enrolling men with  Metastatic Castrate Resistant Prostate Cancer (CRPC). 
The aim of this study is to measure the immune responses to treatment with sipuleucel-T (Provenge).  All participants will receive the drug. 
&#8220;Subjects will [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/11/provenge-open-label-trial/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reactions to Provenge Data</title>
		<link>http://www.psa-rising.com/blog/2009/04/reactions-to-provenge-data/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/reactions-to-provenge-data/#comments</comments>
		<pubDate>Tue, 28 Apr 2009 20:50:30 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1264</guid>
		<description><![CDATA[“These results confirm the clinical value of Provenge to prolong survival in patients with advanced prostate cancer,” said Dr. Philip Kantoff, head of the prostate cancer program and chief of the division of solid tumor oncology at the Dana-Farber Cancer Institute and Harvard Medical School, and a principal investigator of the Provenge study, in a [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/reactions-to-provenge-data/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Investor Interviews Hy Levitsky M.D. on Provenge</title>
		<link>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/#comments</comments>
		<pubDate>Thu, 23 Apr 2009 03:50:15 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Biotech companies]]></category>
		<category><![CDATA[Cancer Treatments]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[trial results]]></category>
		<category><![CDATA[Add new tag]]></category>
		<category><![CDATA[Dendreon IV board]]></category>
		<category><![CDATA[HY Levitsky M.D.]]></category>
		<category><![CDATA[rufustoehee]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=1177</guid>
		<description><![CDATA[A four part interview with  Hy Levitsky M.D., professor of oncology and tumor immunology at Johns Hopkins Medical School and co-inventor GVAX anti-cancer vaccine, is posted on Dendreon Investor Village website.
Interview conducted by rufustoehee, a dentist and Dendreon investor, published 4/22/2009.

By way of introduction, Dr Levitsky&#8217;s bio is posted alphabetically downpage among those of other [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/investorv-interview-with-hy-levitsky/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dendreon Director Sells Stock Options on Day Provenge &#8220;Success&#8221; Touted</title>
		<link>http://www.psa-rising.com/blog/2009/04/dendreon-director-sells-options/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/dendreon-director-sells-options/#comments</comments>
		<pubDate>Thu, 16 Apr 2009 18:51:59 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=973</guid>
		<description><![CDATA[A Dendreon Inc., director, Gerardo Canet, sold over 200,000 stock options in the company on April 14 “pursuant to a Rule 10b5-1 trading plan.” Such trading plans are set up to defend company insiders from allegations of trading on insider information.]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/dendreon-director-sells-options/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Provenge Significantly Extends Survival of Men With Advanced Prostate Cancer, Dendreon Says</title>
		<link>http://www.psa-rising.com/blog/2009/04/951/</link>
		<comments>http://www.psa-rising.com/blog/2009/04/951/#comments</comments>
		<pubDate>Tue, 14 Apr 2009 15:15:45 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Treatments]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=951</guid>
		<description><![CDATA[Dendreon&#8217;s prostate cancer vaccine significantly prolonged the overall survival among 500 men with advanced, metastic  prostate cancer  compared to a placebo, the company said Tuesday.
Results were &#8220;robust&#8221; and &#8220;unambiguous,&#8221; a spokesman said during today&#8217;s (Tues April 14) company broadcast conference call with biotech investment analysts.
&#8220;The successful outcome from the Phase 3 IMPACT study provides validation [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2009/04/951/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Raise A Voice Writes to FDA Advisory Committee</title>
		<link>http://www.psa-rising.com/blog/2007/05/raise-a-voice-writes-to-fda-advisory-committee/</link>
		<comments>http://www.psa-rising.com/blog/2007/05/raise-a-voice-writes-to-fda-advisory-committee/#comments</comments>
		<pubDate>Mon, 07 May 2007 12:03:09 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Awareness Events]]></category>
		<category><![CDATA[Dendreon]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Raise a Voice]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/05/07/raise-a-voice-writes-to-fda-advisory-committee</guid>
		<description><![CDATA[Raise a Voice, an advocacy group for advanced prostate cancer patients, which is calling for patient access to drugs that have passed through Phase I trials, has written a thank you letter  to the FDA Advisory Committee on Dendreon&#8217;s sipuleucel-T (Provenge).

The letter is signed by 19 prostate cancer advocacy groups including US Too International [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/05/raise-a-voice-writes-to-fda-advisory-committee/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
